Patents by Inventor Harald FRICKE

Harald FRICKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody
    Patent number: 11014991
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: May 25, 2021
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jaromir Sykora, Christian Merz, Tim Schnyder, Harald Fricke
  • ANTI-CD95L ANTIBODY
    Publication number: 20200102397
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
    Type: Application
    Filed: September 26, 2019
    Publication date: April 2, 2020
    Inventors: Christian GIEFFERS, Oliver Hill, Meinolf Thiemann, Jaromir Sykora, Christian Merz, Tim Schnyder, Harald Fricke
  • Monoclonal anti-CD95L antibody
    Patent number: 10428154
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: October 1, 2019
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jaromir Sykora, Christian Merz, Tim Schnyder, Harald Fricke
  • Diagnostic anti-CD95L antibody
    Patent number: 10266600
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the diagnosis of a cancer disease.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: April 23, 2019
    Assignee: APOGENIX AG
    Inventors: Harald Fricke, Christian Gieffers, Jaromir Sykora
  • ANTI-CD95L ANTIBODY
    Publication number: 20180208664
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
    Type: Application
    Filed: March 21, 2018
    Publication date: July 26, 2018
    Inventors: Christian GIEFFERS, Oliver HILL, Meinolf THIEMANN, Jaromir SYKORA, Christian MERZ, Tim SCHNYDER, Harald FRICKE
  • INHIBITORS OF THE CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS
    Publication number: 20170166648
    Abstract: The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.
    Type: Application
    Filed: December 28, 2016
    Publication date: June 15, 2017
    Inventors: Harald FRICKE, Michaela FONTENAY, Claudia KUNZ
  • Combination of CD95/CD95L inhibition and Cancer Immunotherapy
    Publication number: 20170106048
    Abstract: The present invention relates to the treatment of cancer using a combination of an inhibitor of the CD95/CD95L signaling system and an immunotherapeutic agent, e.g. a cancer vaccine or a checkpoint inhibitor. Another aspect of the invention is the prognosis of responsiveness of a cancer to the treatment with a combination of a CD95 inhibitor and an immunotherapeutic agent. Further disclosed are preparations and kits for use in these methods.
    Type: Application
    Filed: December 23, 2016
    Publication date: April 20, 2017
    Inventors: Claudia KUNZ, Harald FRICKE, Thomas HÖGER, Juergen GAMER
  • DIAGNOSTIC ANTI-CD95L ANTIBODY
    Publication number: 20170044264
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the diagnosis of a cancer disease.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Inventors: Harald Fricke, Christian GIEFFERS, Jaromir Sykora
  • Inhibitors of the CD95 signaling pathway for treatment of MDS
    Patent number: 9540431
    Abstract: The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: January 10, 2017
    Assignee: Apogenix AG
    Inventors: Harald Fricke, Michaela Fontenay, Claudia Kunz
  • METHOD OF DIAGNOSING CANCER
    Publication number: 20160103132
    Abstract: The present invention relates to a method for diagnosing a cancer disease, comprising (a) determining the expression of CD95L in a cancer sample, and (b) classifying the cancer disease according the level of CD95L expression.
    Type: Application
    Filed: October 27, 2015
    Publication date: April 14, 2016
    Inventors: Harald FRICKE, Christian GIEFFERS, Jaromir SYKORA
  • INHIBITORS OF THE CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS
    Publication number: 20150166632
    Abstract: The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.
    Type: Application
    Filed: July 18, 2013
    Publication date: June 18, 2015
    Applicant: APOGENIX GmbH
    Inventors: Harald Fricke, Michaela Fontenay
  • IL-4 RECEPTOR AND IL-13 AS PROGNOSTIC MARKERS FOR COLON AND PANCREAS TUMORS
    Publication number: 20100111969
    Abstract: The present invention relates to the use of IL-4 receptor and IL-13 expression as diagnostic and/or prognostic markers for tumors, such as colon and pancreas tumors.
    Type: Application
    Filed: October 30, 2009
    Publication date: May 6, 2010
    Applicant: Apogenix GmbH
    Inventors: Harald FRICKE, Marko KORNMANN